Analyst Price Target is $6.83
▲ +659.09% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $6.83, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 659.09% upside from the last price of $0.90.
Current Consensus is
Moderate Buy
The current consensus among 4 contributing investment analysts is to moderate buy stock in Femasys. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Read More
